Galectin Therapeutics’ (GALT) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a report released on Friday morning,Benzinga reports.

Separately, StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th.

Galectin Therapeutics Stock Performance

Shares of GALT stock opened at $1.15 on Friday. The firm has a market capitalization of $72.18 million, a PE ratio of -1.58 and a beta of 0.69. Galectin Therapeutics has a 1 year low of $0.73 and a 1 year high of $4.27. The stock has a fifty day moving average of $2.34 and a two-hundred day moving average of $2.43.

Insider Buying and Selling

In other news, CFO Jack W. Callicutt sold 40,000 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $0.89, for a total value of $35,600.00. Following the completion of the sale, the chief financial officer now owns 7,614 shares of the company’s stock, valued at $6,776.46. This trade represents a 84.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Joel Lewis sold 56,000 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.89, for a total value of $49,840.00. Following the completion of the transaction, the chief executive officer now owns 897,012 shares in the company, valued at $798,340.68. This represents a 5.88 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have bought 15,500 shares of company stock valued at $23,000 and have sold 109,654 shares valued at $97,456. 50.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Galectin Therapeutics

Several large investors have recently made changes to their positions in the company. Marshall Wace LLP acquired a new position in Galectin Therapeutics in the 2nd quarter valued at $43,000. Rhumbline Advisers bought a new stake in Galectin Therapeutics during the 2nd quarter valued at approximately $44,000. Gladstone Institutional Advisory LLC bought a new position in Galectin Therapeutics in the 3rd quarter worth approximately $60,000. Barclays PLC lifted its holdings in shares of Galectin Therapeutics by 309.0% during the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after buying an additional 21,598 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Galectin Therapeutics by 161.3% in the third quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company’s stock valued at $84,000 after acquiring an additional 18,907 shares during the period. Institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.